Member Info for Fredd1eboy

RENEURON Michael Hunt, Chief Financial Officer Oct. 5 | 5:15pm | La Jolla Ballroom 1

I apologise. I accidentally posted on the wrong site. Best wishes freddie

http://www.iii.co.uk/brr-media/447530/valirx-valiseek-clinical-development-update?context=LSE:VAL

....was my trade. Although I have full faith in Reneuron delivering in the long-term, I also believe Valirx is a good short-term bet at 1.04p. I'm not plugging Val, as I've lost a packet on them before, but at the current price, it's my risk!!!! Best of luck all. Freddie

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=COS&ArticleCode=owpxeso4&ArticleHeadline=Study_Update_Patient_Assessments_Completed

snuck in around 12.00 @1.66p.....for info

A pleasure purpleackey and thank you so much for your polite reply. Best wishes Freddie

...is a buy

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=RENE&ArticleCode=vggpuydt&ArticleHeadline=Directors39_Interest_in_Shares_and_Share_Options

I don't report posts. Only those that are rude and destructive. You have added nothing to this board and whilst I can tolerate that, I will not tolerate your hollow personal insults. That's enough said. Freddie

You're only one post on this site in one month says it all. You have no idea at all what you're talking about. Cash in the bank values it at more than the current sp.

Did anyone attend and if so any feedback over and above the RNS. Best wishes. Freddie

http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-AGM-deck-Sep-2017-final.pdf

Agreed. Two measly trades and we are at the top of risers @ 42.86%. It's a disgrace, summing up aim in one word.

Agreed. All going well and the current sp says "just one thing"...BARGAIN". That's why I've been buying at less than 1.8p and will continue to do so as long as the market sp allows.

Cant see them running out of money tipster, that is unless they let their major investors down. too much invested to date to allow the work to be sold on the cheap to others.

Agreed. . .a breath of fresh air following Harper!! Reneuron Group 01 Sep 2017 07:00:05 ReNeuron Group plc RNS Number : 5221P ReNeuron Group plc 01 September 2017 1 September 2017 AIM: RENE ReNeuron Group plc Non-executive Director Appointment ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the appointment of Dr Claudia D'Augusta as a Non-executive Director of the Company, effective from the date of the Company's Annual General Meeting on 6 September 2017. She will also chair the Company's Audit Committee. Dr D'Augusta has over twenty years' experience in corporate finance, capital markets and M&A. She is the Chief Financial Officer of TiGenix NV, a leading international cell therapy company listed on both Euronext Brussels and, more recently, on NASDAQ following a successful US IPO in 2016. TiGenix's lead product has been filed for regulatory approval in Europe for the treatment of a severe complication of Crohn's disease. Before joining TiGenix in 2004, Dr D'Augusta was finance director of Aquanima (Santander Group). Previous experience includes roles in corporate finance and M&A at Deloitte & Touche in Milan and Apax Partners in Madrid. Dr D'Augusta holds a degree in Economics and a Ph.D. in Business Administration from the University of Bocconi, Italy. Commenting on Dr D'Augusta's appointment, John Berriman, Chairman of ReNeuron, said: "I am delighted to welcome Claudia to the Board of the Company, and to its Audit Committee. Her broad and extensive experience in Europe and US corporate finance, in particular in the cell therapy sector, will be invaluable to ReNeuron and its management team." Commenting on her appointment, Dr D'Augusta said: "I look forward to joining the Board of ReNeuron and contributing to the Company as it continues to develop and moves closer to realising value from its novel cell-based therapies targeting areas of unmet medical need."

I'm not being a smartie sheer, but by board...do you mean this board or Rene bod. My reasons for asking.. I'm all for a gentlemanly lse board but also I have a problem with poor shareholder value management, which is clearly the responsibility of the Reneuron Board....and as I'm on the receiving end I'm more than unhappy..."I'm livid". They have time to correct it with some good data and excellent pr, preferably before they award themselves trillions of shares @ 1p. If they don't perform I hold my position....leaches on the backs of the scientists, so cut a few out!

I've recommended both your posts now. Time to call a halt and agree whose able to attend the agm to speak for all us small shareholders.

Guess you're right CH. We are at the mercy of scant trading. A £10 sell could probably wipe off £1m of our value "tongue in cheek". Why is our so so low, I ask myself. Is it...fear...disinterest...I guess a combination. But all are issues that Olav Hellebo can tackle with good pr. If and I hope "If" he is working miracles behind the scenes I'm happy to support his salary. . but as far as his bonus is concerened, it should relate to shareholder value and not leach on the backs of the scientists efforts. Thank goodness we are not in the sights of the short termed as we would be worth nothing by now